Paper36966788
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
Winters N and 14 others. Lancet Respir Med, 2023. Cited by 32 papers, by iCite.
Cite this record
ConductScience Library. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Papers, record 36966788. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36966788
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Latent Tuberculosis | Major topic |
| Tuberculosis | Major topic |
| Humans | |
| Rifampin | |
| Isoniazid | |
| Antitubercular Agents | |
| Drug Therapy, Combination |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CC999999 | Intramural CDC HHS | United States | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 36966789 | Shorter regimens for tuberculosis preventive treatment: piecing together the global implementation jigsaw. | https://conductscience.org/library/papers/36966789 |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25904367 | Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. | Clin Infect Dis | 2015 | https://conductscience.org/library/papers/25904367 | PubMed |
| 2 | 25814376 | WHO's new end TB strategy. | Lancet | 2015 | https://conductscience.org/library/papers/25814376 | PubMed |
| 3 | 1731596 | A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. | Am Rev Respir Dis | 1992 | https://conductscience.org/library/papers/1731596 | PubMed |
| 4 | 17712755 | The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. | Clin Infect Dis | 2007 | https://conductscience.org/library/papers/17712755 | PubMed |
| 5 | 29114781 | Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. | Ann Intern Med | 2017 | https://conductscience.org/library/papers/29114781 | PubMed |
| 6 | 27116943 | A scoping review of indirect comparison methods and applications using individual patient data. | BMC Med Res Methodol | 2016 | https://conductscience.org/library/papers/27116943 | PubMed |
| 7 | 29580819 | Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. | Lancet Infect Dis | 2018 | https://conductscience.org/library/papers/29580819 | PubMed |
| 8 | 17504683 | [Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients]. | Enferm Infecc Microbiol Clin | 2007 | https://conductscience.org/library/papers/17504683 | PubMed |
| 9 | 19017587 | Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. | Ann Intern Med | 2008 | https://conductscience.org/library/papers/19017587 | PubMed |
| 10 | 9295239 | A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. | N Engl J Med | 1997 | https://conductscience.org/library/papers/9295239 | PubMed |
| 11 | 25519784 | Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention. | Int J Tuberc Lung Dis | 2015 | https://conductscience.org/library/papers/25519784 | PubMed |
| 12 | 31462531 | RoB 2: a revised tool for assessing risk of bias in randomised trials. | BMJ | 2019 | https://conductscience.org/library/papers/31462531 | PubMed |
| 13 | 25580725 | Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. | JAMA Pediatr | 2015 | https://conductscience.org/library/papers/25580725 | PubMed |
| 14 | 26951571 | Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. | Clin Infect Dis | 2016 | https://conductscience.org/library/papers/26951571 | PubMed |
| 15 | 29910114 | Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. | Am J Prev Med | 2018 | https://conductscience.org/library/papers/29910114 | PubMed |
| 16 | 18926033 | Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. | Int J Tuberc Lung Dis | 2008 | https://conductscience.org/library/papers/18926033 | PubMed |
| 17 | 11684933 | Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. | AIDS | 2001 | https://conductscience.org/library/papers/11684933 | PubMed |
| 18 | 30067928 | Safety and Side Effects of Rifampin versus Isoniazid in Children. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30067928 | PubMed |
| 19 | 22419641 | Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. | J Correct Health Care | 2012 | https://conductscience.org/library/papers/22419641 | PubMed |
| 20 | 30067931 | Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30067931 | PubMed |
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42942179 | Integrated Structural, Physicochemical, Pharmacokinetic and Pharmacodynamic Evaluation of Substituted Phenylcarbonyloxypiperazinopropanols as Antimycobacterial Agents. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42942179 | PubMed |
| 42872138 | High Initiation but Suboptimal Completion of Tuberculosis-Preventive Treatment Among People Living With HIV on Antiretroviral Therapy, Persistent Tuberculosis Incidence, and Programmatic Implications: Findings From a 2-Year Multicountry Cohort Study. | Open Forum Infect Dis | 2026 | https://conductscience.org/library/papers/42872138 | PubMed |
| 42841008 | Tuberculosis Incidence and Predictors Among People Living With HIV After Isoniazid-Rifapentine (3HP) Preventive Therapy in Ethiopia: A Retrospective Cohort Study. | J Trop Med | 2026 | https://conductscience.org/library/papers/42841008 | PubMed |
| 42758766 | Scaling-up tuberculosis preventive therapy to HIV-negative contacts of bacteriologically confirmed TB cases aged 5 years and above - Lessons from a tuberculosis preventive therapy surge activity in Zambia. | PLOS Glob Public Health | 2026 | https://conductscience.org/library/papers/42758766 | PubMed |
| 42373911 | Breaking barriers: Implementation of a tuberculosis preventive treatment protocol among newly eligible populations with promising results. | Eur J Clin Microbiol Infect Dis | 2026 | https://conductscience.org/library/papers/42373911 | PubMed |
| 42369968 | Infectious Disease Provider Perspectives on Shorter Tuberculosis Treatment Regimens. | Open Forum Infect Dis | 2026 | https://conductscience.org/library/papers/42369968 | PubMed |
| 42136397 | Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial. | Clin Infect Dis | 2026 | https://conductscience.org/library/papers/42136397 | PubMed |
| 42116841 | Tuberculosis Prevention in Pregnant Women Living with HIV: A Review of the Current Management Strategies and Guidance. | Infect Drug Resist | 2026 | https://conductscience.org/library/papers/42116841 | PubMed |
| 42088243 | Acceptance, completion, and safety of the 3HR regimen for latent tuberculosis infection: a prospective cohort study in China. | Front Public Health | 2026 | https://conductscience.org/library/papers/42088243 | PubMed |
| 42077650 | Efficacy, safety, and completion of modified short-course rifapentine and isoniazid for latent tuberculosis infection in patients with high-risk rheumatic disease: a multicentre, open-label, randomized, non-inferiority trial. | EClinicalMedicine | 2026 | https://conductscience.org/library/papers/42077650 | PubMed |
| 41592909 | The implementation of tuberculosis preventive therapy in HIV care clinics in Africa, Asia and Latin America: a multiregional site survey. | BMJ Glob Health | 2026 | https://conductscience.org/library/papers/41592909 | PubMed |
| 41544145 | Identifying missed opportunities in tuberculosis preventive treatment care cascade: Analysis of programme data from Maharashtra, India. | PLOS Glob Public Health | 2026 | https://conductscience.org/library/papers/41544145 | PubMed |
| 41248394 | Functional Outcomes, Lung health and Livelihood Outcomes among people With Tuberculosis (FOLLOW-TB): study protocol for a multicentre, prospective cohort study in Canada. | BMJ Open | 2025 | https://conductscience.org/library/papers/41248394 | PubMed |
| 41191713 | Treatment completion rates and adverse effects of three months of once-weekly isoniazid plus rifapentine for latent tuberculosis infection. | J Bras Pneumol | 2025 | https://conductscience.org/library/papers/41191713 | PubMed |
| 41089227 | Risks and consequences of TB and its prevention in cost-utility analyses among immigrants: a systematic review. | IJTLD Open | 2025 | https://conductscience.org/library/papers/41089227 | PubMed |
| 41059819 | [The effect of the 3HP regimen on the completion of preventive tuberculosis treatment in people living with HIV: a retrospective cohort in Brazil]. | Cad Saude Publica | 2025 | https://conductscience.org/library/papers/41059819 | PubMed |
| 40980570 | Costs of 4 Months of Rifampin Versus 2 Months of Double-dose Rifampin for Tuberculosis Infection: Post-Hoc Analysis of a Phase 2b Randomized Trial. | Open Forum Infect Dis | 2025 | https://conductscience.org/library/papers/40980570 | PubMed |
| 40768149 | Integrating Early Tuberculosis States Into Contact Management in Peru. | JAMA Netw Open | 2025 | https://conductscience.org/library/papers/40768149 | PubMed |
| 40326358 | Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB). | Emerg Microbes Infect | 2025 | https://conductscience.org/library/papers/40326358 | PubMed |
| 40262275 | Prevalence and treatment outcomes of latent tuberculosis infection among older patients with chronic obstructive pulmonary disease in an area with intermediate tuberculosis burden. | Emerg Microbes Infect | 2025 | https://conductscience.org/library/papers/40262275 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36966788
GET https://conductscience.org/api/papers/v1/36966788/references?page=2